View Financial HealthRepligen 配当と自社株買い配当金 基準チェック /06Repligen配当金を支払った記録がありません。主要情報n/a配当利回り0.1%バイバック利回り総株主利回り0.1%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 07An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem. For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million. An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026.お知らせ • Apr 22Repligen Corporation to Report Q1, 2026 Results on May 05, 2026Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026お知らせ • Apr 03Repligen Corporation, Annual General Meeting, May 14, 2026Repligen Corporation, Annual General Meeting, May 14, 2026.お知らせ • Feb 24Repligen Corporation Provides Earnings Guidance for the Full Year 2026Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share.お知らせ • Feb 10Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026お知らせ • Jan 07Repligen Corporation Announces Executive Changes, Effective March 13, 2026On January 6, 2026, Repligen Corporation announced that the Board of Directors has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. Dr. Madaus will succeed Tony J. Hunt, who is currently serving as the Executive Chair of the Board, following his previously announced March 2026 retirement, which shall be on the Effective Date, at which time Mr. Hunt will retire as a member of the Board. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta Inc. and Hologic Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.お知らせ • Dec 17Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality WorkflowsRepligen Corporation announced the launch of three new high-performance chromatography resins: AVIPure®? HiPer™? AAV9 and AVIPure®? Hi Per™? AAV8 affinity resins, along with HiPer™? QA anion-exchange resin, expanding the company's growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™? DuloCore™? base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company's leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.Buy Or Sell Opportunity • Nov 06Now 21% undervaluedOver the last 90 days, the stock has risen 22% to €123. The fair value is estimated to be €155, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.2% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 45% per annum over the same time period.Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.27 (vs US$0.012 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.27 (up from US$0.012 loss in 3Q 2024). Revenue: US$188.8m (up 22% from 3Q 2024). Net income: US$14.9m (up US$15.6m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.お知らせ • Oct 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year, the total reported revenue of $729 million to $737 million, Income from Operations of $50 million to $52 million, net income of $46.5 million to $48 million and Earnings per share - Diluted of $0.82 per share to $0.85 per share.お知らせ • Oct 15Repligen Corporation to Report Q3, 2025 Results on Oct 28, 2025Repligen Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025お知らせ • Jul 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year total reported revenue of $715 million to $735 million, Income from Operations of $51 million- $56 million, net income of $48 million - $51.5 million and Earnings per share - Diluted of $0.85 per share - $0.92 per share.お知らせ • Jul 17Repligen Corporation to Report Q2, 2025 Results on Jul 29, 2025Repligen Corporation announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Jul 29, 2025決済の安定と成長配当データの取得安定した配当: 1RGENの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 1RGENの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Repligen 配当利回り対市場1RGEN 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (1RGEN)n/a市場下位25% (IT)1.7%市場トップ25% (IT)4.6%業界平均 (Life Sciences)0.8%アナリスト予想 (1RGEN) (最長3年)0%注目すべき配当: 1RGENは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 1RGENは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 1RGENの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 1RGENが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YIT 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 12:02終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Repligen Corporation 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29 アナリスト機関Luke SergottBarclaysRobert WassermanBenchmark CompanyHugo SolvetBNP Paribas26 その他のアナリストを表示
お知らせ • May 07An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem. For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million. An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026.
お知らせ • Apr 22Repligen Corporation to Report Q1, 2026 Results on May 05, 2026Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026
お知らせ • Apr 03Repligen Corporation, Annual General Meeting, May 14, 2026Repligen Corporation, Annual General Meeting, May 14, 2026.
お知らせ • Feb 24Repligen Corporation Provides Earnings Guidance for the Full Year 2026Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share.
お知らせ • Feb 10Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026
お知らせ • Jan 07Repligen Corporation Announces Executive Changes, Effective March 13, 2026On January 6, 2026, Repligen Corporation announced that the Board of Directors has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. Dr. Madaus will succeed Tony J. Hunt, who is currently serving as the Executive Chair of the Board, following his previously announced March 2026 retirement, which shall be on the Effective Date, at which time Mr. Hunt will retire as a member of the Board. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta Inc. and Hologic Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.
お知らせ • Dec 17Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality WorkflowsRepligen Corporation announced the launch of three new high-performance chromatography resins: AVIPure®? HiPer™? AAV9 and AVIPure®? Hi Per™? AAV8 affinity resins, along with HiPer™? QA anion-exchange resin, expanding the company's growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™? DuloCore™? base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company's leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.
Buy Or Sell Opportunity • Nov 06Now 21% undervaluedOver the last 90 days, the stock has risen 22% to €123. The fair value is estimated to be €155, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.2% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 45% per annum over the same time period.
Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.27 (vs US$0.012 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.27 (up from US$0.012 loss in 3Q 2024). Revenue: US$188.8m (up 22% from 3Q 2024). Net income: US$14.9m (up US$15.6m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
お知らせ • Oct 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year, the total reported revenue of $729 million to $737 million, Income from Operations of $50 million to $52 million, net income of $46.5 million to $48 million and Earnings per share - Diluted of $0.82 per share to $0.85 per share.
お知らせ • Oct 15Repligen Corporation to Report Q3, 2025 Results on Oct 28, 2025Repligen Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025
お知らせ • Jul 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year total reported revenue of $715 million to $735 million, Income from Operations of $51 million- $56 million, net income of $48 million - $51.5 million and Earnings per share - Diluted of $0.85 per share - $0.92 per share.
お知らせ • Jul 17Repligen Corporation to Report Q2, 2025 Results on Jul 29, 2025Repligen Corporation announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Jul 29, 2025